【导读】恒瑞医药启动港股全球招股 中国基金报记者卢鸰 据悉，恒瑞医药基石投资者按发售价认购或促使其指定实体认购可购入的若干数目的发售股份，以发行 价中端计算，总金额逾41亿港元（约5.33亿美元），认购金额占比达发行规模的43.04%（假设超额配售 权及发售量调整权未行使）。 在业内人士看来，赴香港上市是恒瑞医药出海战略的关键一步。首先，香港资本市场的国际投资者基础 广泛，有助于提升公司在全球医药行业的品牌影响力；其次，此次港股上市可进一步优化资本结构并开 拓新的融资渠道，为公司多元化融资提供助力；最后，赴港上市有助于公司拓展海外业务和国际研发合 作，增强国际布局，进一步实现海外市场的突破，提升公司的全球竞争力。 数据显示，2024年，恒瑞医药的海外收入占比仅为2.56%，百济神州的海外收入占比则高达62.85%。 5月15日早盘，恒瑞医药股价平开，截至记者发稿，公司股价为52.99元，微涨0.17%。 （文章来源：中国基金报） 恒瑞医药5月15日早间发布公告称，公司正式启动H股全球公开发售，计划发行约2.25亿股H股（假设超 额配售权及发售量调整权未行使），其中，香港公开发售占比为5.5%，国际配售占比为9 ...

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-078 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏恒瑞医药股份有限公司（以下简称"公司"）正在进行发行境外上市外资 股（以下简称"H 股"）股票并在香港联合交易所有限公司（以下简称"香港联交 所"）主板挂牌上市（以下简称"本次发行上市"）的相关工作。 在香港联交所网站刊登了申请资料。 江苏恒瑞医药股份有限公司境外发行上市备案通知书》（国合函〔2025〕721 号）。 市的申请。关于本次发行上市的相关进展具体内容详见公司在上海证券交易所网站 （www.sse.com.cn）披露的公告。 江苏恒瑞医药股份有限公司 关于刊发 H 股招股说明书、H 股发行价格区间 及 H 股香港公开发售等事宜的公告 上市 H 股招股说明书，该 H 股招股说明书为根据适用的香港法律法规和香港联交所、 香港证券及期货事务监察委员会的相关规范及要求而刊发，其包含的部分内容可能 与公司先前根据中国法律法规准备或者刊发的相关文件存在一定的差异，包括但不 限于该招股说明书中包含的根据国 ...

恒瑞医药（600276）公告，2025年5月15日，公司按照有关规定在香港联交所网站刊登并派发本次发行 上市H股招股说明书。公司本次H股发行的价格区间初步确定为41.45港元至44.05港元。公司H股香港公 开发售于2025年5月15日开始，预计于2025年5月20日结束，并预计于2025年5月22日前(含当日)公布发 行价格。公司本次发行的H股预计于2025年5月23日在香港联交所挂牌并开始上市交易。 ...

Core Viewpoint - Heng Rui Medicine is launching a global public offering of H-shares, aiming to raise up to HKD 13.08 billion, marking the highest fundraising amount for a pharmaceutical IPO in Hong Kong in the past five years [1][2]. Group 1: IPO Details - The company plans to issue 224,519,800 H-shares, with 5.5% allocated for public sale in Hong Kong and 94.5% for international placement [1]. - The price range for the shares is set between HKD 41.45 and HKD 44.05, with the potential to increase the total shares issued to 296,927,200 if the over-allotment option is fully exercised [1]. - The public offering in Hong Kong will conclude on May 20, 2025, with the final issue price expected to be determined by May 22, 2025 [1]. Group 2: Investor Participation - The IPO has attracted a strong lineup of cornerstone investors, including GIC, Invesco, UBS-GAM, Hillhouse Capital, and Boyu Capital, with total subscriptions exceeding HKD 4.1 billion, accounting for 43.04% of the offering size [2]. - The cornerstone investors will purchase shares at the mid-point of the issue price, indicating strong market confidence in the company [2]. Group 3: Financial Performance - In 2024, the company reported revenue of RMB 27.985 billion, a year-on-year increase of 22.63%, and a net profit of RMB 6.337 billion, up 47.28% [3]. - For Q1 2025, revenue reached RMB 7.206 billion, growing 20.14% year-on-year, while net profit increased by 36.90% to RMB 1.874 billion [3]. - The company has maintained high R&D investment, totaling RMB 8.228 billion in 2024, with a R&D expense ratio consistently above 20% [3]. Group 4: Strategic Importance of Listing - The Hong Kong listing is a crucial step in the company's international expansion strategy, enhancing its brand influence in the global pharmaceutical industry [4]. - The listing will optimize the capital structure and open new financing channels, supporting diversified funding efforts [4]. - It will also facilitate the expansion of overseas business and international R&D collaborations, strengthening the company's global competitiveness [4].

江苏恒瑞医药股份有限公司 关于刊发 H 股招股说明书、H 股发行价格区间 及 H 股香港公开发售等事宜的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏恒瑞医药股份有限公司（以下简称"公司"）正在进行发行境外上市外资 股（以下简称"H 股"）股票并在香港联合交易所有限公司（以下简称"香港联交 所"）主板挂牌上市（以下简称"本次发行上市"）的相关工作。 2025 年 1 月 6 日，公司向香港联交所递交了本次发行上市的申请，并于同日 在香港联交所网站刊登了申请资料。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-078 https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0515/20250515 00020_c.pdf 英文： https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0515/20250515 00019.pdf 需要特别说明的是，本公告仅为 A 股投资者及时了解公司相 ...

Group 1 - The company, Heng Rui Medicine, plans to globally issue approximately 225 million H-shares, with 12.3486 million shares available in Hong Kong and around 212 million shares for international offering [1] - The expected pricing date for the shares is May 21, 2025, with a price range of HKD 41.45 to HKD 44.05 per share [1] - The company has established a cornerstone investment agreement, with cornerstone investors agreeing to subscribe for shares totaling USD 533 million (approximately HKD 4.131 billion) [3] Group 2 - The company is recognized as a leading innovative pharmaceutical enterprise rooted in China, ranking highly in terms of innovative drug revenue and the number of new drug entities in clinical or later stages [2] - The company has committed to significant R&D investment, with 29.4% of total revenue allocated to R&D in 2024 [2] - The net proceeds from the global offering are expected to be approximately HKD 94.578 billion (assuming a mid-price of HKD 42.75 per share) or HKD 125.282 billion if the overallotment option is fully exercised [4] Group 3 - The company intends to allocate approximately 45% of the net proceeds for clinical research of innovative and pipeline drugs, 20% for the development of innovative drugs, and 10% for potential global acquisitions and collaborations [4] - Additionally, around 15% of the funds will be used for building new production and R&D facilities in China and overseas, with the remaining 10% for working capital and other general corporate purposes [4]

集团估计，经扣除承销佣金及其他集团就全球发售应付的估计费用后，集团将自全球发售获得募集资金 净额约94.58亿港元(假设发售价为每股H股42.75港元，即本招股章程所述发售价范围的中位数，并假设 发售量调整权及超额配股权未获行使)或125.28亿港元(倘发售量调整权及超额配股权获悉数行使)。集团 拟将全球发售募集资金净额用于以下用途：约75%将用于集团的研发计划;约15%将用于在中国和海外市 场建设新的生产和研发设施;余下约10%将用作集团的营运资金及其他一般企业用途。 集团已与GIC、Invesco Advisers、UBS AM Singapore等基石投资者订立基石投资协议，据此，基石投资 者已同意遵照若干条件，按发售价认购或促使其指定实体认购若干数目的发售股份(向下约整至最接近 每手200股H股的完整买卖单位)，总金额为5.33亿美元(假设发售价为每股发售股份42.75港元(即发售价 范围的中位数)。 对创新的这一执着追求，从集团的资金投入中可见一斑，2024年集团的研发投入(包括研发费用及资本 化研发支出)占总收入的百分比达29.4%。此外，集团致力于为股东带来可观的回报。自A股上市以来， 集团的累 ...

恒瑞医药：在港上市拟发行2.245亿股 发行价不超44.05港元 金十数据5月15日讯，恒瑞医药港交所公告：在港上市拟发行2.245亿股H股（视乎发售量调整权及超额 配股权行使与否而定），发行价将不会超过44.05港元/股，不低于41.45港元/股。预计5月23日开始在港 交所买卖。 ...

Core Viewpoint - The recent surge of A-share companies pursuing IPOs in Hong Kong, including the notable case of Hengrui Medicine, highlights a strategic move towards internationalization and capital optimization in the pharmaceutical sector [1][3]. Company Overview - Hengrui Medicine, established in 1970, is an innovative international pharmaceutical company focused on the research, production, and promotion of high-quality drugs across various therapeutic areas, including oncology, metabolism, cardiovascular diseases, immunology, respiratory diseases, and neuroscience [2]. - The company has established 14 R&D centers globally and has developed multiple technology platforms for drug development, including PROTAC, peptide drugs, monoclonal antibodies, and AI drug discovery [2]. IPO Details - Hengrui Medicine has officially passed the listing hearing with the Hong Kong Stock Exchange and is expected to launch its IPO roadshow this month, aiming to raise approximately $2 billion (around 14.5 billion RMB) [1]. - The funds raised will be used to optimize the capital structure, explore new financing channels, and support R&D innovation, product commercialization, and operational needs [1][4]. Financial Performance - In the 2024 annual report, Hengrui Medicine reported a revenue of 27.985 billion RMB, a year-on-year increase of 22.63%, and a net profit of 6.337 billion RMB, up 47.28% [4]. - The Q1 2025 report showed a revenue of 7.206 billion RMB, reflecting a 20.14% year-on-year growth, with a net profit of 1.874 billion RMB, a 36.90% increase [4]. Strategic Implications - The move to list in Hong Kong is seen as a catalyst for Hengrui Medicine's international expansion, enhancing its visibility among international investors and improving its global brand image [5]. - The dual listing strategy ("A+H") is part of the company's broader "innovation + internationalization" strategy, positioning internationalization as a key focus for growth [3].

智通财经5月15日电，恒瑞医药香港IPO发行价区间为每股41.45-44.05港元。 ...